found Documents: 808

Announcements & Press Releases, Regulatory Notice | 17 Aug 2021

Election of language and means of receipt of corporate communications

3 items

HKEX Announcement (PDF)Letter and reply form to new registered shareholders (PDF)Notification letter and request form to non-registered holders (PDF)

Announcements & Press Releases, Oncology / Immunology | 9 Aug 2021

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

2 items

- Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio - - Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milesto

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 4 Aug 2021

Monthly Return

1 item

HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Jul 2021

Total Voting Rights

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Friday, July 30, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) hereby notifies the market that as at July 30, 2021, the issued share capital of HUTCHMED consisted of 864,11

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 28 Jul 2021

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

1 item

HKEX Announcement (PDF)

Announcements & Press Releases, Group | 28 Jul 2021

HUTCHMED Reports 2021 Interim Results and Provides Business Updates

2 items

ELUNATE® in-market sales1 rose 186%, reflecting impact of in-house sales force Received 1st approval in China for ORPATHYS® and 2nd approval in China for SULANDA® U.S. and E.U. applications for surufatinib both accepted Raised $615m2 gross pr

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Jul 2021

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

2 items

— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbor MET amplification — Hong Kong, Shanghai & Florham Park, NJ —

LSE RNS Announcement (PDF)HKEX - Voluntary Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Jul 2021

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, July 23, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces that the stabilization period in connection with the Global Offering ended on J

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 16 Jul 2021

TR-1: Standard form for notification of major holdings

2 items

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Jul 2021

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

2 items

– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 14 Jul 2021

TR-1: Standard form for notification of major holdings

2 items

HKEX Overseas Regulatory Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Jul 2021

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, July 13, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and high

HKEX - Voluntary Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 12 Jul 2021

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

2 items

Hong Kong, Shanghai, & Florham Park, NJ — Monday, July 12, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise of the over-allotment option of the Global Offering. Th

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jul 2021

Monthly Return

1 item

Election of language and means of receipt of corporate communications

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

Monthly Return

Total Voting Rights

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

HUTCHMED Reports 2021 Interim Results and Provides Business Updates

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

TR-1: Standard form for notification of major holdings

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

TR-1: Standard form for notification of major holdings

First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

Monthly Return

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China

TR-1: Standard form for notification of major holdings

HUTCHMED to Announce 2021 Half-Year Financial Results

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Total Voting Rights

Holdings in Company

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

Blocklisting Six Monthly Return

List of Directors and Their Roles and Functions

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

HUTCHMED Announces Pricing of Global Offering

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

Disclosure Update

HUTCHMED Launches Hong Kong Initial Public Offering

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

HUTCHMED to Attend Upcoming Investor Conferences

Change of Company Name

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

Results of Annual General Meeting

Vesting of awards under the Long Term Incentive Plan

Notification of Dilution of Voting Rights

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies

2020 Annual Report and Notice of Annual General Meeting

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

Vesting of awards under the Long Term Incentive Plan

Chi-Med becomes HUTCHMED

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

Chi-Med to Announce 2020 Final Results

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases